Datasea Inc. announced that its China‑based operations have moved two acoustic‑driven brain‑computer interface (BCI) initiatives from foundational neural‑signal enhancement to engineering‑level system integration. The first initiative targets assistive communication for stroke survivors, translating EEG signals into structured control commands for external devices. The second initiative focuses on upper‑limb rehabilitation, aligning decoded neural signals with robotic execution logic to create a closed‑loop training framework.
The company’s acoustic‑intelligence platform underpins both projects. By employing ultrasonic and infrasound techniques, Datasea improves signal quality and stability, enabling more reliable translation of neural intent into device commands. The technology builds on a core acoustic‑driven BCI framework disclosed in late 2025 and represents a key step toward commercial deployment in health‑robotics and other embodied‑intelligence systems.
Datasea’s progress fits within its dual‑engine strategy, which centers on an Acoustic High‑Tech segment and an AI Multimodal Digitalization segment. In FY2025, the company generated $71.62 million in revenue, a 198.7% increase from $23.97 million in FY2024. The AI Multimodal Digitalization segment contributed $70.68 million, while the Acoustic High‑Tech segment added only $0.5 million. Gross margin improved from 0.93% in Q1 FY2025 to 8.46% in Q1 FY2026, reflecting a shift toward higher‑margin products and services. Although Datasea has historically reported net losses, it achieved adjusted net‑income breakeven in Q4 FY2025, signaling a transition toward profitability.
CEO Zhixin Liu emphasized that the BCI advancements reinforce the company’s core technology barriers and clarify its long‑term strategy of combining acoustic technology with multi‑scenario applications. Liu noted that the new BCI initiatives could diversify revenue streams beyond the AI‑centric business, potentially unlocking high‑margin medical and assistive‑technology markets that are projected to reach $15‑20 billion by 2030. The partnership with Nanjing Linghang, a domestic health‑robotics manufacturer, is a critical validation step that could accelerate commercialization of the acoustic‑BCI platform.
The announcement follows a positive market reaction to the earlier Nanjing Linghang collaboration, which drove an 11.5% surge in Datasea’s stock on January 5, 2026. While the company’s stock remains volatile and analyst coverage is limited, the new BCI milestones reinforce investor interest in Datasea’s emerging technologies. However, challenges persist: the company’s revenue is still heavily concentrated in the AI segment, and the Acoustic High‑Tech segment remains nascent. Management acknowledges the need to validate the BCI technology for commercial success while navigating ongoing net‑loss pressures and a reliance on a single high‑growth segment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.